JPS6277322A - Aging preventing agent - Google Patents
Aging preventing agentInfo
- Publication number
- JPS6277322A JPS6277322A JP60214882A JP21488285A JPS6277322A JP S6277322 A JPS6277322 A JP S6277322A JP 60214882 A JP60214882 A JP 60214882A JP 21488285 A JP21488285 A JP 21488285A JP S6277322 A JPS6277322 A JP S6277322A
- Authority
- JP
- Japan
- Prior art keywords
- fructooligosaccharide
- amount
- bifidobacteria
- fructose
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
この発明は老化防止剤に関する。そｎはいわゆる健康食
品に属するものでなく、特定の病気を治す医薬でもな（
、人体の各器官、細胞の老化を進める有害物質発生源で
ある腸内細菌ケ制圧するため、継続的に食事の都度、服
用する内服剤である。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) This invention relates to anti-aging agents. It does not belong to so-called health foods, nor is it a medicine that cures a specific disease (
It is an oral medication that is taken continuously with each meal to control intestinal bacteria, which are the source of harmful substances that accelerate the aging of organs and cells in the human body.
（従来の技術）
人が地球上に現れて以来数百万年、求めて未だに児出丁
事ができないものに不老不死の置薬がある。こｎン求め
た秦の始皇帝も、戦争や食中毒、悪疫流行等による死を
薬によって免ｎ得るという考えであったと思わｎる。(Prior art) One thing that has been sought for millions of years since humans first appeared on earth and still cannot be found is the potion for immortality. I think Qin Shihuang, who requested this, also believed that medicine could be used to absolve death from war, food poisoning, epidemics, etc.
この発明の究極目的も、老化を防ぐ薬剤の開発により、
少（とも人体の天寿といわｎる百数十年の寿命を実現す
る事にある。The ultimate purpose of this invention is to develop a drug that prevents aging.
The goal is to achieve a lifespan of over 100 years, which is known as the human body's natural lifespan.
さて、この発明の背景となる従来技術は、明治製菓株式
会社によるフラクトオリゴ糖の工業生産実現であり、こ
の糖の用法を示した著書「腸が弱いのはビフイズ菌が減
るからだ」（岡田淳著、昭和５ｑ年１０月、青春出版社
発行）である。The prior art that forms the background of this invention is the realization of industrial production of fructooligosaccharide by Meiji Seika Co., Ltd., and the book ``The intestine is weak because the number of Bifid bacteria decreases'' (written by Jun Okada), which shows how to use this sugar. , published by Seishun Publishing Co., Ltd., October 1932).
明治製菓、健康産業部発行の説明書の要部ン引用すると
、「メイオリゴは、フラクトオリゴ糖ン主成分とする、
健康シロップで丁。そのまＮい１コｙけ、ビフイズ菌の
栄養になり、気になるカロリーや虫歯も安心。「腸の時
代」にマツチした手軽でうｎしい味方で丁。」とある。To quote the main part of the instruction manual published by Meiji Seika and the Health Industry Department, ``Mayoligo is a product whose main component is fructooligosaccharide.
Ding with healthy syrup. Sprinkle just 1 ounce of N and it becomes nutrients for Bifid bacteria, so you don't have to worry about calories or cavities. An easy and delicious ally that is perfect for the ``age of intestines.''"a.
またその「召しあがり方」としては、［コーヒーや紅茶
、牛乳やヨーグルトなどに砂糖と同じようにお使いくだ
さい。」とある。Also, as for how to enjoy it, please use it in the same way as sugar in coffee, tea, milk, yogurt, etc. "a.
この製品には液と、粉末に近い微小顆粒と、７個で７．
２ｇの立方体キャンデー等がある。液は一回中、フラク
トオリゴ糖９ｇ、顆粒は一回中’１．５ｇ、キャンデー
は一個中にダ、、？＋７だけ含んでいろ。This product includes a liquid and micro granules that are almost powder-like, and contains 7 pieces.
There are 2g cube candy etc. The liquid contains 9g of fructooligosaccharide, the granules contain 1.5g per serving, and the candy contains 9g per serving. Include only +7.
こうして工業生産可能になったフラクトオリゴ糖の効果
、用法ケ示す上記著書の内容は次に示す。The contents of the above-mentioned book, which shows the effects and usage of fructooligosaccharide, which has thus become industrially producible, are as follows.
題名や各章の見出しは出版社により、や＼宣伝具のある
ものになっているが、その著者は大病院の微生物学検査
料医長であり、その内容も科学的裏付けによって述べら
ｎている。The titles and chapter headings have been changed by the publisher and are somewhat promotional, but the author is a medical director for microbiology testing at a large hospital, and the contents are based on scientific evidence. .
第１章「あなたの腸が弱いのはビフィズス菌不足」
第２章「野菜や水分、薬で便秘を治している人のこの恐
い害」
第３章「臨床報告９便秘症はふつうの人の６倍老化ケ早
める」
第４章「新物質（フラクトオリゴ糖）は７日間で便秘２
治し強い体にする」
さて第１章の中のビフィズス菌の説明では、「私は、丁
でに、ビフィズス菌はいわゆる善玉菌であると述べまし
１こ。この善玉菌という意味は、我々の体内で役に立つ
働きをするという事で丁が、そｎともうひとつ、体内で
いっさいの有害物を作らないという事にも注目し１こい
。Chapter 1: ``The reason your intestines are weak is due to a lack of Bifidobacterium.'' Chapter 2: ``This is a terrible harm to people who treat constipation with vegetables, water, and medicine.'' Chapter 3: ``Clinical report 9: Constipation is common in normal people.'' 6 times faster aging” Chapter 4 “New substance (fructooligosaccharide) causes constipation in 7 days 2
In chapter 1, in the explanation of bifidobacteria, I mentioned that bifidobacteria are so-called good bacteria1. Ding has a useful function in the body, but it is also worth noting that it does not produce any harmful substances in the body.
大腸菌なはじめとする悪玉菌のほうは、タンパク質ン分
解して、アンモニア、アミン、硫化水素といった腐敗成
分ン出てので有害な存在と見なさｎているわけで丁。Bad bacteria such as Escherichia coli are considered harmful because they decompose proteins and release putrefactive substances such as ammonia, amines, and hydrogen sulfide.
便秘をしないためには０６．（中略）０１．腸内で、善
玉菌軍のビフィズス菌が、悪玉菌軍乞抑えて優位に立っ
ていることが不可欠なのです。06. To avoid constipation. (omitted) 01. It is essential that the good bacteria, Bifidobacterium, dominates the intestine over the bad bacteria.
ビフィズス菌のチャームポイントは、まス腸の中で糖ケ
分解して、乳酸と酢酸ケ一対−の割で作り出てことで丁
。１０．（中略）１０．つまり、ビフィズス菌が多けｎ
ば、その産出する酸のおかげで、いっそう悪玉菌よりも
優位に立てるという好循環も生まれて（るので丁。The charm point of Bifidobacterium is that it breaks down sugars in the trout intestine and produces a ratio of lactic acid and acetic acid. 10. (omitted) 10. In other words, there are many bifidobacteria.
In addition, thanks to the acid it produces, a virtuous cycle is created in which it becomes even more dominant over bad bacteria.
加えて、腸内のＰＨが酸性に傾いてき１こ場合、腸のせ
ん動運動が活発になって（るというメカニズムもありま
す。」
「あなたの便秘の原因は、実は、腸内菌叢のアンバラン
スにある。そこで便秘ン治丁にはどうしたらよいかとい
うと、腸内にビフィズス菌をふやしてやることがベスト
。こ又までは十分おわかりいただけ１こことと思いま丁
。」［フラクトオリゴ糖が、ビフィズス菌ンふや丁こと
に役立つと結論づけるまでには、まだ二つの問題が残さ
γしていま丁。In addition, there is a mechanism in which when the pH in the intestines becomes acidic, the peristaltic movement of the intestines becomes active.''The cause of your constipation is actually an imbalance in the intestinal flora. It's all about balance.The best way to deal with constipation is to increase the number of bifidobacteria in the intestines.I hope you have understood this well.'' [Fructooligo There are still two issues left before we can conclude that sugars are beneficial for bifidobacteria.
まずひとつは、は１こして、他の細菌がフラクトオリゴ
糖をエサにすることかないのか、という点で丁。０１．
（中略）００．フラクトオリゴ糖ｙｔモっともよく利用
するのはビフィズス菌であるということがわかりまし１
こ。The first question is whether other bacteria can feed on fructooligosaccharides. 01.
(omitted) 00. I found out that Bifidobacterium is the most commonly used fructooligosaccharide.
child.
その他、乳酸菌、バクテロイデス、腸球菌に利用さｎろ
ことはあるもの又、ビフィズス菌はどではない。ま１こ
、悪玉菌といえる大腸菌やウェルシュ菌には利用さｎな
い、という結果も出ていまｊ。In addition, it may be used for lactic acid bacteria, Bacteroides, and enterococci, but not for bifidobacteria. However, some results have shown that it is not used against E. coli and Clostridium perfringens, which can be called bad bacteria.
でも問題はもうひとつ残さハ、ています。そのフラクト
オリゴ糖ケロからとりい７”Ｌ ７ｊとしても、小腸ま
での間に消化吸収されてしまい、ビフィズス菌の棲んで
いる大腸までは届かない、ないしは届いたとしてもほん
のわずかではないか。But one more problem remains. Even if you take 7"L 7J from that fructooligosaccharide, it will be digested and absorbed before reaching the small intestine, and it will not reach the large intestine where bifidobacteria live, or even if it does, it will only reach the small amount.
０１０、ということです。８１．（中略）００．フラク
トオリゴ糖だけに関しては、なんともうまい具合いに、
腸管（小腸、大腸！含めて）では吸収さｎないことが、
研究の結果わかったので丁。That means 010. 81. (omitted) 00. As far as fructooligosaccharide is concerned, it is in a very good condition.
It is not absorbed in the intestinal tract (including the small intestine and large intestine!)
I found this out as a result of my research.
」 添付し１こ第１図の説明部分は次のようになっている。” The explanation of the attached Figure 1 is as follows.
［フラクトオリゴ糖の効果ケ確かめる実験として、もう
ひとつ、今度は、実際に私自身が手かげたものケご紹介
しましょう。[As an experiment to confirm the effects of fructooligosaccharides, I would like to introduce one that I actually did myself.
今度の実験対象は、２３人の老人で丁が、フラクトオリ
ゴ糖ｇグラムケ含有する水ようかん娑、全員に一日一回
、二週間続けて摂取してもらいまし１こ。The subjects of this experiment were 23 elderly people who were asked to ingest a water yokan containing fructooligosaccharides once a day for two consecutive weeks.
そして便を取って検査してみ１こところ、摂取前に便／
グラム当り１００ｇ、ｇ乗個（約６億３０００万個）だ
ったビフィズス菌が、四日後には１０の９．６乗イ固（
約ｔｉｏ億個）にまでふえ、二週間後には１０の９．７
乗個（約５０億１００Ｑ万個）に増加しました（２３人
の平均値）。００．（中略）００．早い人では、なんと
四日目ぐらいから便秘解消効果が見らｎｌ−週間目では
、はとんどの人が、便秘から解放さｎていま丁。」
「−日にグラム（必替量の四倍）以上という多ゴはン摂
取したケースでは、下痢になることもあるということが
わかりました。」
第２図は「ビフィズス菌の数で老化がわかるｊとして引
用さ几たもので出典の記述はない。Then, I took a sample of the stool and tested it, and found that before ingestion, the stool/
The number of Bifidobacterium per gram was 100g to the power of g (approximately 630 million), but four days later, the number of bifidobacteria was 10 to the power of 9.6 (approximately 630 million).
After two weeks, the number of 9.7 out of 10
The number of cases has increased to 5,010,000,000,000,000 (average value for 23 people). 00. (omitted) 00. For those who take it early, the effect of relieving constipation can be seen from around the fourth day, and by the first week, most people are relieved of constipation. "It has been found that cases of ingesting more than 1 gram (4 times the required amount) of gohan per day can cause diarrhea." It has been cited as a book that shows that there is no mention of the source.
この著書の最終部分にフラクトオリゴ糖の用法が次のよ
うに記さ几ている。At the end of this book, the usage of fructooligosaccharide is described as follows.
「さて問題の一日の摂取量と摂取期間で丁が、便秘の症
状などに応じて個人差がある１こめ、決めるのはなかな
かむずかしいので丁。しかし、一応の基準ということで
いえば、−日タグラムなまず一週間続けてとってくださ
い。１こいていの便秘ならば、この量と期間でも、十分
解消効果が見もｎにとと思います。もし、そｎだけのガ
と期間で効北が今ひとつという場合（ま、７０グラム程
度まで量ンふやしてみるか、ハ）と）いは摂取Ｊυ１間
ケさらに延長してみ石とよいでしよう。``Now, the question of daily intake and intake period varies from person to person depending on symptoms of constipation, etc., so it is quite difficult to determine.However, as a general rule, - Please take the daily dose for a week.If you have severe constipation, I think this amount and period will be enough to relieve your constipation. If it's not good enough (maybe try increasing the amount to about 70 grams, c), then try extending the intake for an additional 1 hour.
００．（中略）０１０便秘が治ったあとは便秘予防を兼
ね、腸内の健康を保つ土で習慣的に摂取するという形で
もい〜と思い一！ｊ″ｆ０フラクトオリゴ糖は、便秘の
治療効果ン持つものＮ、薬ではなくあくまでも食品で丁
。」
第３図は明治製菓が行なった調査として引用さ几１こ図
で、実験対象者は仙秘症ケ訴える４９人、フラクトオリ
ゴ糖の量は症状がひどい人はど多（与えることを原則と
し、２３名に一日一回りｇ、４１２名にｇｇ、 −名
に７２ｇ、−名にｌ乙ｇ、二連間続けπものである。00. (Omitted) 010 After your constipation is cured, I thought you could habitually take soil to prevent constipation and keep your intestines healthy! Fructooligosaccharide has a therapeutic effect on constipation.It is not a drug, but a food.'' Figure 3 is a diagram cited as a survey conducted by Meiji Seika, and the experimental subjects were Of the 49 people who complained of symptoms, the amount of fructooligosaccharide was given to those with severe symptoms (as a general rule, it should be given once a day to 23 people, 1 g to 412 people, 72 g to 1 person, 1 g to 1 person) , two consecutive π ones.
’Ｉｇ摂取者は７ａの人が便秘改善、ｇｇでは７９係、
／コｇでは１００％、／ＡＱでも７００係の改善率であ
る。'For those who took Ig, constipation improved in 7a, 79 in gg,
The improvement rate is 100% in /Cog and 700 in /AQ.
（発明が解決しようとする問題点）
フラクトオリゴ糖の工業生産実現という大きな成果に比
べ、生産さｎｌこフラクトオリゴ糖の用途、用法の研究
が遅ｎている。具体的にいえば、フラクトオリゴ糖を使
って腸内ビフィズス菌を増殖させるのは、ビフィズス菌
に何ンさせるためなのか、そしてフラクトオリゴ糖ｔど
のように使えば、その目的にかなうようビフィズス菌ン
増殖させらｎるか、といった研究があまり進んでいない
ようである。(Problems to be Solved by the Invention) Compared to the great achievement of realizing industrial production of fructooligosaccharides, research on the uses and uses of the produced fructooligosaccharides has been slow. Specifically, what is the purpose of using fructooligosaccharides to grow intestinal bifidobacteria, and how should fructooligosaccharides be used to grow bifidobacteria to meet that purpose? There does not seem to be much progress in research on whether or not this is the case.
この発明は上の問題に一応の解答７出し、今後、工業生
産さ１しるフラクトオリゴ噌１ミとして、保健上、最も
望ましい供給形態ン提案するものである。This invention provides a tentative answer to the above problems, and proposes the most desirable form of supply from a health standpoint, in the form of 1 ml of industrially produced fructooligo.
（問題点を解決するための手段） この発明は蔗糖に果糖伝位酵累ン働かせ、ｒｉ′４′。(Means for solving problems) In this invention, sucrose is subjected to fructose transfer fermentation to produce ri'4'.
糖のフラクトース残基に１〜３個の７ラクトスケ結合さ
せた小糖類であるフラクトオリコ゛糖を、−粒にｏ、／
ｇＬ八θへの範囲の定力上ずつ含ませ一７′ 吐・ζ
１欣内服ａｌｌと１−Ｔ−こンケ特徴とする老化防止剤
である。Fructo-olicosaccharide, which is a small sugar with 1 to 3 7-lactoske bonds attached to the fructose residue of sugar, is added to the grains.
Include each constant force in the range to gL8θ17' Discharge ζ
It is an anti-aging agent that can be taken internally and has the characteristics of 1-T-Konke.
（作 用）
従来のフラクトオリゴ糖の供給形態（工前述のとおり、
液は一回中、フラクトオリゴ糖ｑｇ。(Function) Conventional fructooligosaccharide supply form (as mentioned above,
The liquid is qg of fructooligosaccharide each time.
微小ａ粒は一回中に四糖を’１．ｓｇ、キャンデーは一
個中にｒｌ、３ｇだけ含んでいるが、こｎらは前記著書
において、工業生産さｎｌこフラクトオリゴ糖が健康食
品に属する事ン強調し、用法として一日一回、５１７程
度７！ｌ−摂取するとし、上記液は家庭の料理に大サジ
何杯という使い方ケ指示してい石のと一致する。Micro A grains contain 1.4% of tetrasaccharide in one serving. One candy contains only 3g of RL, but in the above book they emphasize that industrially produced fructooligosaccharides belong to health foods, and the usage is once a day, about 517g. 7! This is consistent with the instructions on how many tablespoons of the above liquid should be used in home cooking.
こ几は便秘ン治丁健康食品の摂り方としては後述するよ
うに有効なことが理解できろ。Understand that this is an effective way to take healthy foods to prevent constipation, as will be explained later.
さて、この発明はフラクトオリゴ糖を整腸用食品ではな
（、老化防止剤とする１こめ、こｎ’ｌｌ−粒にフラク
トオリゴ糖０．／〜ｉ、ｏ ｇの範囲内の定楚だけ含む
粒剤とした。こ瓦に粒剤とは、錠剤、顆粒、カプセル人
、その他、そのま−服用できる固形のものすべてン指丁
。従来−包又は−個に９．３〜？ｇ であつ１こフラク
トオリゴ糖ン、−粒０．１〜／、Ｏｇに変えただけの変
化により、どのような新しい作用が生じたかを以下に述
べよう。Now, this invention is not about fructooligosaccharide as a food for intestinal regulation. Granules include tablets, granules, capsules, and any other solid product that can be taken as is. Conventionally, a package or piece weighs between 9.3 and 1 g. The following describes what new effects were produced by simply changing the fructooligosaccharide to 0.1 to 0.0 g/g.
人体から排出さｒ′ｌ−る糞便の１０−２０ 係は生き
た細菌である。その人の腸内細菌のうち１０Ｑｂがビフ
ィズス菌であｎば、毎日、糞便の量の／〜−係という大
量のビフィズス菌が排出さｎている事になる。日常、フ
ラクトオリゴ糖を摂取しなくても、その排出量と同量の
ビフィズス菌が、大腸へ来１こ食物渣ン栄養源として、
毎日増殖しているから、はに定量のビフィズス菌が腸内
に維持されていたのである。About 10 to 20 percent of the feces excreted from the human body are living bacteria. If 10 Qb of a person's intestinal bacteria are bifidobacteria, then a large amount of bifidobacteria will be excreted every day, equivalent to the amount of feces. Even if you do not ingest fructooligosaccharide on a daily basis, the same amount of bifidobacteria as the amount excreted will come to the large intestine and serve as a food source of nutrients.
Because they proliferate every day, a large amount of Bifidobacterium was maintained in the intestines.
従来のように一日一回、大量のフラクトオリゴ糖が胃袋
内の食物に拡散して、腸へ下る場合、その分の食物法が
大腸を通過している間だけ、腸内ビフィズス菌が大増殖
する。同じ食物法により従来より多量のビフィズス菌が
直腸へ運ばｎ排出するが、まだ相当に増殖したビフィズ
ス菌が大腸に残る。しかし、その後の食事でとった食物
にはフラクトオリゴ糖が含まｎないため、その食物法が
大腸ケ通過すると、折角、腸内に増殖、残留し１こビフ
ィズス菌が、次々と直腸へ運び出さｎ、排出さｎるから
、−日一回のフラクトオＩＪ コ籾ｉ摂取では腸内ビフ
ィズス菌の責は一日週期の山と谷ンもっ事になる３、山
と谷があ。Traditionally, when a large amount of fructooligosaccharide diffuses into the food in the stomach pouch once a day and goes down to the intestines, the intestinal bifidobacteria proliferate only while the food is passing through the large intestine. do. With the same food method, a larger amount of Bifidobacteria than before is transported to the rectum and excreted, but Bifidobacteria that have grown considerably still remain in the large intestine. However, since the food eaten after that meal does not contain fructooligosaccharides, when the food passes through the large intestine, the remaining Bifidobacterium bacteria multiply in the intestine and are carried out one after another to the rectum. Because it is excreted, once a day fructo-IJ is ingested with rice, the intestinal bifidobacteria are responsible for the peaks and troughs of the day and week.
−っても、その山の時、つまり大量のビフィズス菌が生
じた時、腸内の酸がふえて腸のせん動し高めるから、便
秘の治療には有効に働（。-However, when there is a mountain of bifidobacteria, the acid in the intestines increases and the intestines become more active, so it is effective in treating constipation.
しかし老化防止の立場からいえば、ビフィズス菌が多い
時、腐敗菌等、老化物質ケ全身へ送る細菌が制圧さｎて
も、ビフィズス菌が減っ１こ時は、はとんど前どおりに
老化物質が出ろ事になるから効力がない。However, from the standpoint of anti-aging, when bifidobacteria are abundant, even if the bacteria that send aging substances to the whole body, such as putrefactive bacteria, are suppressed, when bifidobacteria are reduced, aging will continue as before. It has no effect because the substance comes out.
フラクトオリゴ糖ヲ小量含む粒剤としＴ−この発明の場
合、薬剤として手軽に毎食時ＩＪＲ用するので、大腸を
通過する食物法は常時、はｇ定量のフラクトオリゴ糖を
含む１こめ、老化物質が発生する期間がない。In the case of this invention, it is easy to take IJR at every meal as a drug, so the food method that passes through the large intestine is always a granule containing a small amount of fructooligosaccharides, which is free from aging substances. There is no period in which it occurs.
この発明の粒剤服用前に保持し１こ腸内ビフィズス菌の
量に、服用後、フラクトオリゴ糖といつ最高の栄養源に
より増殖しくその一部は排出さｎる）残存した菌の量が
加わるため、ビフィズス菌の細菌種制圧作用が強化さｎ
、老化物質の体内拡散が減少する。この老化物質の減少
が人体各部、細胞の老化現象ン阻止、又は減少するので
ある。After taking the granules of this invention, the amount of bifidobacteria in the intestine that is retained before taking the tablet is added to the amount of remaining bacteria (which proliferates due to fructooligosaccharide and the best nutritional source and some of it is excreted) after taking the tablet. Therefore, the bacterial species suppression effect of Bifidobacterium is strengthened.
, the diffusion of aging substances in the body is reduced. This reduction in aging substances prevents or reduces the aging phenomenon of cells and parts of the human body.
ビフィズス菌の作用ン技報堂出版「栄養学ハンドブック
」から抜書きすると、
［Ｉ：ビフィズス菌はまった（病源性を有せず、宿主に
害を及ぼさない。The effects of Bifidobacteria are excerpted from the ``Nutrition Handbook'' published by Gihodo.
■：ビフイズス菌は他種の細菌の腸内増殖ケ防止する。■: Bifidobacterium prevents the proliferation of other types of bacteria in the intestines.
■：ピフィズス菌は腸内でたえず酸を産生することによ
って、他の菌ンおさえるのみならず、腸を刺戟して腸の
せん動を適当に高め、さらにカルシウムや鉄塩の吸収を
富めろ。■: By constantly producing acid in the intestine, Pifidobacterium not only suppresses other bacteria, but also stimulates the intestine, increases intestinal peristalsis, and further increases the absorption of calcium and iron salts. .
■：ビフイズス菌はビタミンＢ％合成する。■: Bifidobacterium synthesizes vitamin B%.
Ｖ：ビフィズス菌叢では腸内腐敗現象を生じにくい。V: Bifidobacterial flora is less likely to cause intestinal putrefaction.
腸内腐敗産物としては、タンパク分解物に出来するアン
モニア、硫化水素、インドール、スカトール、アミン類
、メタン、メチルメルカン°タンなと゛があげら才ｔ・
・・。−１この発明は上の■を除く各作用を活用する。Intestinal spoilage products include ammonia, hydrogen sulfide, indole, skatole, amines, methane, and methylmercanthane produced from protein decomposition products.
.... -1 This invention utilizes each of the above effects except for ■.
フラクトオリゴ糖の毎食時服用により、大腸を通る食物
法が常にフラクトメリゴ糖を含むため、ビフィズス菌増
殖量がその搬出量を上まわり、腸内ビフィズス菌の漸増
娑持続する。そして他の条件が加わらなけｎば、ビフィ
ズス菌と、フラクトオリゴ糖７摂取できる無害菌とが、
腸内から有害菌ン駆逐するに至るのである。By taking fructooligosaccharides with every meal, the food that passes through the large intestine always contains fructomerygosaccharides, so the amount of bifidobacteria that grows exceeds the amount that is exported, and the gradual increase in intestinal bifidobacteria continues. And unless other conditions are added, bifidobacteria and harmless bacteria that can ingest fructooligosaccharide 7,
This will eliminate harmful bacteria from the intestines.
（実施例）
この発明の老化防止剤はフラクトオリゴ糖乞０．１〜７
．０ｇ含む粒剤で、例えば−・粒にｏ、、ｒｇだけ含む
場合、荀食時三粒ずつ服用丁ｎば一日に八ｇｇのフラク
トオリゴ糖をとつ１こことになる。(Example) The anti-aging agent of this invention has a fructooligosaccharide concentration of 0.1 to 7
．． For example, if the granules contain 0g, for example, if the granules contain only o,,rg, then if you take 3 tablets each time you eat, you will take 8g of fructooligosaccharides per day.
−日一回の糞便排出忙ン７００ｇ、こハによって排出さ
ｎる生き１こ細菌の量は、その１０％として１０ｇ１そ
のうちビフィズス菌は７０％として／ｇとなる。腸内ビ
フィズス菌の邪ケ増減なく糾持するには、排出五七に切
・しい７ｇだけ肘１殖させｎばよい。- The amount of live bacteria excreted by 700 g of fecal excretion once a day is 10% (10%)/g (70% of which is bifidobacteria). In order to maintain the intestinal bifidobacterium without any harmful increase or decrease, all you need to do is to grow 7g of bifidobacteria per elbow, which is essential for elimination.
もともと腸内に生じているビフィズス菌に、通常食品の
渣ン栄養源として増殖し、便と共にわ１出さｎて、ｉｔ
ｒ定量に保持さｎるのであるから、この発明の粒剤服
用により腸内ビフィズス菌の定量がふえても、その排出
量の相当な部分は通常食品の渣により増殖補給されろ。Bifidobacterium, which originally occurs in the intestines, proliferates as a nutrient source in the residue of food and is excreted with stool.
Therefore, even if the amount of intestinal bifidobacteria increases by taking the granules of the present invention, a considerable portion of the amount excreted will be replenished by normal food waste.
通常のビフィズス菌排出量より増大し１こ分だけ、フラ
クトオリゴ糖により栄養補給して、増殖量を増してやｎ
ばよいので、上述のＷ 出舒／ｇの場合、その何壬かを
フラクトオリゴ糖で増殖させ几ばよい。The amount of bifidobacteria excreted is increased by 1 minute compared to the normal amount, and the amount of growth is increased by providing nutrition with fructooligosaccharide.
Therefore, in the case of the above-mentioned W yield/g, it is sufficient to propagate some of them with fructooligosaccharide.
この発明の粒剤服用により、腸内ビフィズス菌の量が服
用前より倍増した状態で、−日の排出ｆＡ ／ ｇと丁
ｎば、ふえた分の排出量ｏ、ｓｇだけフラクトオリゴ糖
でもって増殖させｎばよい訳である。By taking the granules of this invention, the amount of bifidobacteria in the intestine is doubled compared to before taking it, and if the amount of excreted fA / g on - day increases, the amount of excreted o, sg increases by the increased amount o, sg, and grows with fructooligosaccharides. All you have to do is let it happen.
フラクトオリゴ糖がビフィズス菌にとって最高の活力源
である事は実験上疑いないが、こｎ乞θ、ｓｇ増殖させ
るのに、どｎだげのフラクトオリゴ糖乞要するかは、後
述千るような実験研究で求めねばならない。仮りに増殖
量と等是を多少上まわるものと丁ｎば、上記の０．−ｇ
入り粒剤を毎食時、／〜コ粒服用す几ばよい。There is no experimental doubt that fructooligosaccharide is the best source of vitality for bifidobacteria, but how much fructooligosaccharide is required for the growth of Bifidobacterium is subject to a thousand experimental studies, which will be described later. You have to find it. If the amount of proliferation is slightly higher than the above 0. -g
It is best to take the granules with each meal.
フラクトオリゴ糖の毎食時服用乞続け、腸内有害菌の漸
減から完全駆逐を達成し１こ場合、−日の糞便量の７０
〜−ＩＯ係がビフィズス菌と無害菌のυト出ｊ泡名ｔに
なる。By continuing to take fructooligosaccharide with every meal, we achieved complete eradication from the gradual reduction of harmful intestinal bacteria.
~-The IO staff will produce bifidobacteria and harmless bacteria.
糞便量ン１００ Ｑとすると、排出菌量は１０〜ｘｔｇ
という太番、になり、毎日、そｎだけの耐力ｔ（ビフィ
ズス菌＋無害菌）を増殖させねば、有害菌が復活してく
る。If the amount of feces is n100Q, the amount of bacteria excreted is 10~xtg
If we don't grow enough tolerance t (bifidobacteria + harmless bacteria) every day, the harmful bacteria will come back.
このように大量増殖が必要になると、前述のように７ラ
クトオリゴ糖服用量とビフィズス菌無害菌の増殖量との
関係を調べる事が不可欠となる。こｎは、その方面の研
知者に任せる事柄であるが、毎日の糞便の中のビフィズ
ス菌、無害菌、及び有害菌のＲｙｒ調べ、こｎとフラク
トオリゴ糖服用量との関係から、有害菌を生せしめない
最小限の毎食時服用ｆＦｔＹ求めｎばよい。When such large-scale proliferation is required, it is essential to investigate the relationship between the dose of 7-lactooligosaccharide and the amount of growth of harmless Bifidobacterium bacteria, as described above. This is a matter that is left to experts in the field, but from the relationship between bifidobacteria, harmless bacteria, and harmful bacteria in daily feces, and the amount of fructooligosaccharides taken, harmful bacteria have been detected. All you have to do is find the minimum amount of fFtY to be taken at each meal that does not cause this.
大量服用の場合、フラクトオリゴ糖含有量／ｇの粒剤が
使いよい。For large doses, granules with fructooligosaccharide content/g are recommended.
この発明の人体実験として、発明者自身とその家族、従
業員が、市販品のフラクトオリゴ糖液を計量しや丁い７
ｇずつ継続的に毎食時服用した。皆、健康体であるため
明確な効果はいえないが、なんとなく気分も体も爽快で
あるという。そｎは断食して宿便ケ排出した後のような
爽快感である。確に有害ａ菌の巣（つである宿便が排出
さ几、腸内からの有害物質放出がなくなるから、この発
明により同様の効果ケあげた時と似た感じになるのであ
ろう。As a human experiment of this invention, the inventor himself, his family, and employees weighed a commercially available fructooligosaccharide solution.
gram was taken continuously with each meal. Since they are all in good health, it is difficult to say that there are clear effects, but they say that they feel refreshed both physically and mentally. It's a refreshing feeling, like after fasting and expelling fecal impaction. It is true that the fecal impaction, which is a nest of harmful a-bacteria, is expelled, and the release of harmful substances from the intestines is eliminated, so this invention will probably give you a feeling similar to when the same effect was achieved.
（発明の効果）
この発明は百数十才の天寿を全うすべき人体が、より早
く死亡する主因は、腸内細菌から出て全身へ回る有害物
質による老化現象である。(Effects of the Invention) This invention shows that the main reason why humans, who should live a natural life of over 100 years old, die earlier is the aging phenomenon caused by harmful substances released from intestinal bacteria and distributed throughout the body.
とり認識にもとづき、従来断片的にとらえらｎていた腸
内ビフィズス菌の詩作用のうち、その増殖により有害細
菌の絶対量ヶ減少させ、制圧し得る点ン活用し、生物学
的に老化物質の発生、拡散を防止又は減少する具体策を
示しアこ。Based on this recognition, we will utilize the biological effects of intestinal bifidobacteria, which have been only partially understood in the past, to reduce the absolute amount of harmful bacteria and control them through their proliferation, and to treat them as biologically aging substances. Indicate specific measures to prevent or reduce the occurrence and spread of
フラクトオリゴ糖は人体にも、有害細菌にも吸収さｎず
、ｆ、−ｒビフィズス菌、無害菌にだけ吸収さｎるとい
う特性を生かして腸内ビフィズス菌を増殖させる方法は
公知であるが、そのビフィズス菌により老化現象ン防ぐ
には、−日一回のフラクトオリゴ糖摂取でなく、毎食時
、服用しなげｎば、腸内菌量に一日週期の高低ン生じ、
老化物質の阻止効果に乏しくなる原理乞解明し１こ。There is a known method for growing intestinal bifidobacteria by taking advantage of the characteristic that fructooligosaccharides are not absorbed by the human body or by harmful bacteria, but only by f, -r bifidobacteria and harmless bacteria. In order to prevent aging due to bifidobacteria, - If you do not take fructooligosaccharide once a day, but with every meal, the amount of intestinal bacteria will fluctuate throughout the day and week.
The principle behind the lack of effectiveness in inhibiting aging substances has been clarified.
この発明の粒剤は現在の市販品に比べ、−粒内のフラク
トオリゴ糖が著しく少いだけの違いであるが、こｎによ
って従来の一日一回摂取ケ、毎食時服用に変える効果は
、老化防止上絶大である。従来、多量のフラクトオリゴ
糖ン摂取しても、−日一回である１こめ有害菌制圧作用
が間欠的になり、老化防止効果に乏しかつ１こ。この発
明により比較的小量のフラクトオリゴ糖でも、４ノア食
時服用により腸内食物渣ン常に富化し、高水準で腸内ビ
フィズス菌を絹持するから、有害菌制圧作用が有効にと
（持さｎ、老化防止作用ケ不変に丁すのである。The difference between the granules of this invention compared to current commercially available products is that there is significantly less fructooligosaccharide in the granules, but this has the effect of changing from the conventional once-a-day intake to every meal. It is extremely effective in preventing aging. Conventionally, even if a large amount of fructooligosaccharides were ingested, the effect of suppressing harmful bacteria, which was once a day, was intermittent, and the anti-aging effect was poor. With this invention, even a relatively small amount of fructooligosaccharide can be taken at mealtimes to constantly enrich the intestinal food residue and maintain a high level of intestinal bifidobacteria, thereby effectively suppressing harmful bacteria. The anti-aging effect remains unchanged.
老化防止ケ進めｎば、老化による自然死は防げるので、
この発明は、人類の夢であった不老不死の置薬を現実化
した最初のものといへ得る。If we take steps to prevent aging, we can prevent natural death due to aging.
This invention is the first to realize humankind's dream of immortality.
２：ｌ！１〜３図は著書「腸が弱いのはビフィズス菌が
こりるからだ」の第１Ｉ７頁、第１．？７頁、及び第、
２０７頁の複写図である。
特許出願人 商 野 鉄 雄
同 代理人 弁理士 福 １）信 行
間 代理人 弁理士 福 １）武 逆
向 代理人 弁理士 福 １）賢 三
第１図 図面の浄書（内容に変更なし）Ｔｈフラクト
オリゴ糖による腸内細菌叢の変動手続補正書（自発）
昭和６０年１１月６日2:l! Figures 1 to 3 are from the book ``The intestines are weak because bifidobacteria are stiff'', page 1I7, 1. ? Page 7, and No.
This is a copy of page 207. Patent Applicant Tetsu Shono Yudo Agent Patent Attorney Fuku 1) Nobu Gyakuyuki Agent Patent Attorney Fuku 1) Ken San Figure 1 Engraving of drawings (no change in content) Th fructooligosaccharides Amended procedure for changes in intestinal flora (voluntary) November 6, 1985
Claims (1)
に１〜３個のフラクトースを結合させた小糖類であるフ
ラクトオリゴ糖を、一粒に０．１ｇ〜１．０ｇの範囲の
定量ずつ含ませて、粒状内服剤としたことを特徴とする
老化防止剤。Each tablet contains a fixed amount of fructo-oligosaccharides in the range of 0.1g to 1.0g, which is a small sugar made by activating fructose transferase and bonding 1 to 3 fructose to the fructose residue of sucrose. , an anti-aging agent characterized by being made into a granular oral preparation.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60214882A JPS6277322A (en) | 1985-09-30 | 1985-09-30 | Aging preventing agent |
| GB08622227A GB2182558A (en) | 1985-09-30 | 1986-09-16 | Oral fructo-oligosaccharide pharmaceutical compositions |
| DE19863632791 DE3632791A1 (en) | 1985-09-30 | 1986-09-26 | AGENT AGAINST AGE CHANGES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60214882A JPS6277322A (en) | 1985-09-30 | 1985-09-30 | Aging preventing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6277322A true JPS6277322A (en) | 1987-04-09 |
Family
ID=16663126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60214882A Pending JPS6277322A (en) | 1985-09-30 | 1985-09-30 | Aging preventing agent |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS6277322A (en) |
| DE (1) | DE3632791A1 (en) |
| GB (1) | GB2182558A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0832651A1 (en) * | 1995-05-31 | 1998-04-01 | Meiji Seika Kaisha Ltd. | Inhibitor for lipid peroxide increase |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987124A (en) * | 1987-10-13 | 1991-01-22 | Coors Biotech, Inc. | Method for inhibiting the growth of salmonella |
| US5002759A (en) * | 1989-07-25 | 1991-03-26 | Colgate-Palmolive Company | Oligosaccharide inhibition of Streptococcus pyogenes adhesion |
| EP0447125B1 (en) * | 1990-03-08 | 1995-07-19 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Process for preparing lactosucrose high-content powder and use of said powder |
| DE19716731A1 (en) * | 1997-04-14 | 1998-10-15 | Biopract Gmbh | Process for the enzymatic production of fructosyl compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3066516D1 (en) * | 1979-11-07 | 1984-03-15 | Tate & Lyle Plc | Production of isomaltulose |
| JPS5840065A (en) * | 1981-09-01 | 1983-03-08 | Meiji Seika Kaisha Ltd | Low-caloric sweetening agent and preparation of low- caloric food and drink with the same |
-
1985
- 1985-09-30 JP JP60214882A patent/JPS6277322A/en active Pending
-
1986
- 1986-09-16 GB GB08622227A patent/GB2182558A/en not_active Withdrawn
- 1986-09-26 DE DE19863632791 patent/DE3632791A1/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0832651A1 (en) * | 1995-05-31 | 1998-04-01 | Meiji Seika Kaisha Ltd. | Inhibitor for lipid peroxide increase |
| EP0832651A4 (en) * | 1995-05-31 | 2002-02-06 | Meiji Seika Kaisha | Inhibitor for lipid peroxide increase |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3632791A1 (en) | 1987-04-30 |
| GB8622227D0 (en) | 1986-10-22 |
| GB2182558A (en) | 1987-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11351206B2 (en) | Probiotic sports nutrition compositions | |
| RU2468808C2 (en) | Method of treating or preventing systemic inflammation | |
| CN100355420C (en) | Leucine-enriched nutritional compositions | |
| Balch | Prescription for nutritional healing | |
| JP5497634B2 (en) | Probiotics in pre-operative and / or post-operative environments | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| US9271958B2 (en) | Amino acid supplementation for a healthy microbiota ecosystem | |
| WO2002007533A2 (en) | Nutritional composition | |
| CN109430407A (en) | Probiotic combinations preparation | |
| KR102295696B1 (en) | Oral solution powder composition for fatigue reduction and method of preparing the same | |
| CN103190483A (en) | Children growth promotion milk tea | |
| JPS6277322A (en) | Aging preventing agent | |
| US20060210606A1 (en) | Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood | |
| JPH10306028A (en) | Drug for controlling intestinal function by lipid digestive absorbent inhibition | |
| WO2006006267A1 (en) | Antistress agent | |
| JPH0995448A (en) | Increase in biotin concentration in blood and biotin-containing beverage or food product | |
| CN104222272A (en) | Probiotic beverage containing entermorpha prolifera | |
| Singh¹ et al. | Effects of prebiotics on git and human health: a review | |
| TWM536946U (en) | Food structure containing probiotic of arabinose | |
| Friedhoff | Biochemical effects of experimental diets | |
| CN101415414B (en) | Use of citrulline for preparing drug for treating and correcting arginine lack in sepsis patient | |
| JP2005239686A (en) | Body fat combustion promotion composition and food or medicine containing the same | |
| Adams | Formulating combination digestive health products | |
| Elbostany | EFFECT OF PRO AND PRE–BIOTIC SUPPLEMENTATIONS IN WEANING FOODS ON SOME MINERAL ABSORPTION | |
| JP2024508402A (en) | Compositions and methods using a combination of oleuropein and vitamin B6 |